Loncastuximab tesirine
Contents
Description
Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting CD19-positive B-cell malignancies. It delivers a pyrrolobenzodiazepine (PBD) dimer payload specifically to cancer cells. Approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, it offers a novel mechanism for heavily pretreated patients.
Indications & Therapeutic Use
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Loncastuximab tesirine — GNH India
6 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Loncastuximab tesirine products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | loncastuximab tesirine |
| Brands | 1 brand available |
| Active Ingredient | loncastuximab tesirine-lpyl |
| Drug Class | Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) |
| Manufacturer | ADC Therapeutics |
| Dosage Forms | Intravenous infusion, 10mg lyophilized powder |
| Medical Code | L01FX22 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved (2021), EMA Approved (2022) |
| Clinical Trial | NCT03589469 |
| Countries | 5 countries |